delavirdine + nelfinavir + didanosine

delavirdine + nelfinavir + didanosine is a combination of three antiretroviral agents used in highly active antiretroviral therapy (HAART) for the treatment of HIV-1 infection. - **Delavirdine** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase and inhibits viral RNA-dependent DNA polymerase activity by causing conformational changes, thereby blocking viral replication. - **Nelfinavir** is a protease inhibitor that prevents the cleavage of HIV-1 polyproteins, resulting in noninfectious viral particles. - **Didanosine** is a nucleoside analog reverse transcriptase inhibitor (NRTI) that is incorporated into viral DNA, causing chain termination during viral replication. The combination aims to suppress HIV replication by targeting multiple steps in the viral lifecycle. Drug-drug interactions can occur among these agents, requiring careful dose timing (e.g., didanosine should be separated from delavirdine administration by at least 1 hour)[2][4][5]. There is evidence of additive or synergistic in vitro antiviral activity among these agents[4]. The main indication is treatment of HIV-1 infection in adults and pediatric patients, as part of multidrug regimens[2][4][5].